RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

1) Gfp: My bet is that it is non-CNS. And, with all due respect (and you are due plenty)--the 'calpain spectrin protein breakdown' concept is a nonevent according to people I know who have worked with AMPA-modulators and do NOT work for Cortex. It's one less thing to worry about. Let it go.....

2) <<We know Cortex is seeking to end the ongoing R+D collaboration early, but that Servier will still own the Euro neurodegenerative and anxiety rights. As we know, their S-18986 compound doesn't fall within the existing agreement, so I was wondering if you thought Servier might seek an updated agreement for S-18986 sooner rather than later>>

If this were baseball, it would look like a distinct trade possibility, don't you think?

3) Nobody knows the results of the newly-done animal sacrifices, the current stage is where they disassemble those rats and primates, taking tissue slices from each one, from all relevant organs. There are no results yet. However, if the 'consensus report' from the earlier set that Stoll referred to had raised other/new red flags, I would think that would be as material an event as there can be. The question may not relate to the 'subtlety' of the histopathological finding, but its causal attribution. If they previously had found liver pathology in one monkey, is it due to CX717? Age? Heavy drinking? Previously, Cortex and its consultants concluded that it was not due to CX717. The FDA wants more data proving the negative. That's why they are looking to see if the finding is replicated. It was not--IMHO based on the press release--found in the reexamination of the previous set of primates. If it is not found in the new set being examined--the hold will be lifted.

NeuroInvestment